FENGYUAN PHARMACEUTICAL released its performance for the first three quarters, with a net profit attributable to the parent company of 100 million yuan, a year-on-year decrease of 31.92%
According to the Zhitong Finance APP, FENGYUAN PHARMACEUTICAL released its third-quarter report for 2025. In the first three quarters, the company achieved an operating income of 3.125 billion yuan, a year-on-year decrease of 4.18%. The net profit attributable to shareholders of the listed company was 100 million yuan, a year-on-year decrease of 31.92%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 74.9151 million yuan, a year-on-year decrease of 36.39%
According to the Zhitong Finance APP, FENGYUAN PHARMACEUTICAL (000153.SZ) released its third-quarter report for 2025. In the first three quarters, the company achieved an operating income of 3.125 billion yuan, a year-on-year decrease of 4.18%. The net profit attributable to shareholders of the listed company was 100 million yuan, a year-on-year decrease of 31.92%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 74.9151 million yuan, a year-on-year decrease of 36.39%
